115 related articles for article (PubMed ID: 26171935)
1. Expression of pEGFR and pAKT as response-predictive biomarkers for RAS wild-type patients to anti-EGFR monoclonal antibodies in metastatic colorectal cancers.
Harlé A; Salleron J; Perkins G; Pilati C; Blons H; Laurent-Puig P; Merlin JL
Br J Cancer; 2015 Aug; 113(4):680-5. PubMed ID: 26171935
[TBL] [Abstract][Full Text] [Related]
2. Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti-EGFR antibodies in colorectal cancer.
Perkins G; Lièvre A; Ramacci C; Méatchi T; de Reynies A; Emile JF; Boige V; Tomasic G; Bachet JB; Bibeau F; Bouché O; Penault-Llorca F; Merlin JL; Laurent-Puig P
Int J Cancer; 2010 Sep; 127(6):1321-31. PubMed ID: 20049837
[TBL] [Abstract][Full Text] [Related]
3. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.
Benvenuti S; Sartore-Bianchi A; Di Nicolantonio F; Zanon C; Moroni M; Veronese S; Siena S; Bardelli A
Cancer Res; 2007 Mar; 67(6):2643-8. PubMed ID: 17363584
[TBL] [Abstract][Full Text] [Related]
4. Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer.
Rowland A; Dias MM; Wiese MD; Kichenadasse G; McKinnon RA; Karapetis CS; Sorich MJ
Br J Cancer; 2015 Jun; 112(12):1888-94. PubMed ID: 25989278
[TBL] [Abstract][Full Text] [Related]
5. Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer.
Ogino S; Meyerhardt JA; Cantor M; Brahmandam M; Clark JW; Namgyal C; Kawasaki T; Kinsella K; Michelini AL; Enzinger PC; Kulke MH; Ryan DP; Loda M; Fuchs CS
Clin Cancer Res; 2005 Sep; 11(18):6650-6. PubMed ID: 16166444
[TBL] [Abstract][Full Text] [Related]
6. Predictive and prognostic roles of BRAF mutation in patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a meta-analysis.
Xu Q; Xu AT; Zhu MM; Tong JL; Xu XT; Ran ZH
J Dig Dis; 2013 Aug; 14(8):409-16. PubMed ID: 23615046
[TBL] [Abstract][Full Text] [Related]
7. Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients.
Yaeger R; Cercek A; O'Reilly EM; Reidy DL; Kemeny N; Wolinsky T; Capanu M; Gollub MJ; Rosen N; Berger MF; Lacouture ME; Vakiani E; Saltz LB
Clin Cancer Res; 2015 Mar; 21(6):1313-20. PubMed ID: 25589621
[TBL] [Abstract][Full Text] [Related]
8. Predictive biomarkers of clinical response to targeted antibodies in colorectal cancer.
Chua W; Moore MM; Charles KA; Clarke SJ
Curr Opin Mol Ther; 2009 Dec; 11(6):611-22. PubMed ID: 20072938
[TBL] [Abstract][Full Text] [Related]
9. Coexpression of biological key modulators in primary colorectal carcinomas and related metastatic sites: implications for treatment with cetuximab.
Barbier A; Domont J; Magné N; Goldmard JL; Genestie C; Hannoun C; Vaillant JC; Bellanger A; Khayat D; Capron F; Spano JP
Bull Cancer; 2010 Feb; 97(2):E9-E15. PubMed ID: 20085858
[TBL] [Abstract][Full Text] [Related]
10. Spectrum of Gene Mutations in Colorectal Cancer: Implications for Treatment.
Dienstmann R; Tabernero J
Cancer J; 2016; 22(3):149-55. PubMed ID: 27341591
[TBL] [Abstract][Full Text] [Related]
11. EGFR Downregulation after Anti-EGFR Therapy Predicts the Antitumor Effect in Colorectal Cancer.
Okada Y; Kimura T; Nakagawa T; Okamoto K; Fukuya A; Goji T; Fujimoto S; Sogabe M; Miyamoto H; Muguruma N; Tsuji Y; Okahisa T; Takayama T
Mol Cancer Res; 2017 Oct; 15(10):1445-1454. PubMed ID: 28698359
[TBL] [Abstract][Full Text] [Related]
12. Identification of Targetable Kinase Alterations in Patients with Colorectal Carcinoma That are Preferentially Associated with Wild-Type RAS/RAF.
Hechtman JF; Zehir A; Yaeger R; Wang L; Middha S; Zheng T; Hyman DM; Solit D; Arcila ME; Borsu L; Shia J; Vakiani E; Saltz L; Ladanyi M
Mol Cancer Res; 2016 Mar; 14(3):296-301. PubMed ID: 26660078
[TBL] [Abstract][Full Text] [Related]
13. The dark side of the moon: the PI3K/PTEN/AKT pathway in colorectal carcinoma.
Silvestris N; Tommasi S; Petriella D; Santini D; Fistola E; Russo A; Numico G; Tonini G; Maiello E; Colucci G
Oncology; 2009; 77 Suppl 1():69-74. PubMed ID: 20130434
[TBL] [Abstract][Full Text] [Related]
14. EGFR FISH in colorectal cancer: what is the current reality?
Moroni M; Sartore-Bianchi A; Veronese S; Siena S
Lancet Oncol; 2008 May; 9(5):402-3. PubMed ID: 18452847
[No Abstract] [Full Text] [Related]
15. Significance of Phosphorylated Epidermal Growth Factor Receptor and Its Signal Transducers in Human Soft Tissue Sarcoma.
Yang JL; Gupta RD; Goldstein D; Crowe PJ
Int J Mol Sci; 2017 May; 18(6):. PubMed ID: 28556791
[No Abstract] [Full Text] [Related]
16. Plasma Dynamics of RAS/RAF Mutations in Patients With Metastatic Colorectal Cancer Receiving Chemotherapy and Anti-EGFR Treatment.
Thomsen CB; Andersen RF; Lindebjerg J; Hansen TF; Jensen LH; Jakobsen A
Clin Colorectal Cancer; 2019 Mar; 18(1):28-33.e3. PubMed ID: 30459076
[TBL] [Abstract][Full Text] [Related]
17. Primary tumor site and anti-EGFR monoclonal antibody benefit in metastatic colorectal cancer: a meta-analysis.
Li D; Fu Q; Li M; Li J; Yin C; Zhao J; Li F
Future Oncol; 2017 May; 13(12):1115-1127. PubMed ID: 28110551
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of resistance to anti-EGFR therapy in colorectal cancer.
Zhao B; Wang L; Qiu H; Zhang M; Sun L; Peng P; Yu Q; Yuan X
Oncotarget; 2017 Jan; 8(3):3980-4000. PubMed ID: 28002810
[TBL] [Abstract][Full Text] [Related]
19. [Colorectal cancer chemotherapy and anti-EGFR therapy].
Tsuji A
Gan To Kagaku Ryoho; 2011 Jun; 38(6):901-6. PubMed ID: 21677479
[TBL] [Abstract][Full Text] [Related]
20. Potential predictive markers of response to EGFR-targeted therapies in colorectal cancer.
Spano JP; Milano G; Vignot S; Khayat D
Crit Rev Oncol Hematol; 2008 Apr; 66(1):21-30. PubMed ID: 18206383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
